Milestone Pharmaceuticals Inc

NASDAQ:MIST   3:59:44 PM EDT
5.67
+0.13 (+2.35%)
Products

Milestone Pharmaceuticals Announces Exclusive License Agreement With Ji Xing Pharmaceuticals To Develop And Commercialize Etripamil For PSVT In Greater China

Published: 05/17/2021 11:27 GMT
Milestone Pharmaceuticals Inc (MIST) - Milestone Pharmaceuticals Announces Exclusive License Agreement With Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for Psvt in Greater China.
Milestone Pharmaceuticals Inc - Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for Patients With Psvt in Greater China.
Milestone Pharmaceuticals Inc - to Receive a $15 Million Upfront Cash Payment and a $5 Million Equity Investment by Rtw Investments, Lp.
Milestone Pharmaceuticals Inc - Eligible to Receive Up to $107.5 Million in Milestone Payments and Royalties on Future Sales of Etripamil in Greater China.